J. Michael McIntosh,
MD
No Rating Available?
0
out of
5
Patient Rating
In order to provide our patients and visitors with the most accurate and useful information, we only post physician satisfaction data when a physician has received a minimum of 30 returned surveys. For this provider, we have not yet received the
minimum.
Languages Spoken: English
J. Michael McIntosh, MD, graduated from the University of California at Los Angeles Medical School, completed residency training at the University of Colorado and is board-certified in general adult psychiatry. He is Professor with tenure in the Department of Psychiatry and Research Professor in the Department of Biology. Dr. McIntosh is also the Medical Director of the SLVAMC Behavioral Health Clinic where he sees medically complex patients with co-morbid psychiatric conditions. He is ranked by US News and World Reports among the top 1% of doctors in the United States.
Clinical Locations
Psychiatry
801-581-7951
Specialties
Board Certification and Academic Information
| Academic Departments | Psychiatry
-
Professor Biology - Research Professor |
| Academic Divisions | Adult Psychiatry |
| Board Certification | American Board of Psychiatry & Neurology (Psychiatry) |
J. Michael McIntosh, MD, graduated from the University of California at Los Angeles Medical School, completed residency training at the University of Colorado and is board-certified in general adult psychiatry. He is Professor with tenure in the Department of Psychiatry and Research Professor in the Department of Biology. Dr. McIntosh is also the Medical Director of the SLVAMC Behavioral Health Clinic where he sees medically complex patients with co-morbid psychiatric conditions. He is ranked by US News and World Reports among the top 1% of doctors in the United States.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Psychiatry
-
Professor Biology - Research Professor |
| Academic Divisions | Adult Psychiatry |
| Board Certification | American Board of Psychiatry & Neurology (Psychiatry) |
Research Interests
- Structure and function of neuronal nicotinic acetylcholine receptors
Education History
| Residency | University of Utah School of Medicine Psychiatry Resident, 1992 |
| Residency | University of Colorado at Denver and Health Sciences Center Psychiatry Resident, 1991 |
| Internship | University of Colorado at Denver and Health Sciences Center Psychiatry Intern, 1988 |
| Professional Medical | University of California - Los Angeles Medicine M.D., 1987 |
| Undergraduate | University of Utah Biology B.S., 1983 |
Selected Publications - Journal Articles
Journal Article
- Richter K, Papke RL, Stokes C, Roy DC, Espinosa ES, Wolf PMK, Hecker A, Liese J, Singh VK, Padberg W, Schlter KD, Rohde M, McIntosh JM, Morley BJ, Horenstein NA, Grau V, Simard AR (2022). Comparison of the Anti-inflammatory Properties of Two Nicotinic Acetylcholine Receptor Ligands, Phosphocholine and pCF3-diEPP. Front Cell Neurosci, 16, 779081.
- Edinger F, Schmitt C, Koch C, McIntosh JM, Janciauskiene S, Markmann M, Sander M, Padberg W, Grau V (2021). Application of alpha1-antitrypsin in a rat model of veno-arterial extracorporeal membrane oxygenation. Sci Rep, 11(1), 15849.
- Fisher F, Zhang Y, Vincent PFY, Gajewiak J, Gordon TJ, Glowatzki E, Fuchs PA, McIntosh JM (2021). Cy3-RgIA-5727 Labels and Inhibits α9-Containing nAChRs of Cochlear Hair Cells. Front Cell Neurosci, 15, 697560.
- Paguigan ND, Tun JO, Leavitt LS, Lin Z, Chase K, Dowell C, Deering-Rice CE, Lim AL, Karthikeyan M, Hughen RW, Zhang J, Peterson RT, Reilly CA, Light AR, Raghuraman S, McIntosh JM, Olivera BM, Schmidt EW (2021). Nicotinic Acetylcholine Receptor Partial Antagonist Polyamides from Tunicates and Their Predatory Sea Slugs. ACS Chem Neurosci, 12(14), 2693-2704.
- Gajewiak J, Christensen SB, Dowell C, Hararah F, Fisher F, Huynh PN, Olivera BM, McIntosh JM (2021). Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism. J Med Chem, 64(13), 9271-9278.
- Zheng N, Christensen SB, Dowell C, Purushottam L, Skalicky JJ, McIntosh JM, Chou DH (2021). Discovery of Methylene Thioacetal-Incorporated α-RgIA Analogues as Potent and Stable Antagonists of the Human α9α10 Nicotinic Acetylcholine Receptor for the Treatment of Neuropathic Pain. J Med Chem, 64(13), 9513-9524.
- Sethuramanujam S, Matsumoto A, deRosenroll G, Murphy-Baum B, Grosman C, McIntosh JM, Jing M, Li Y, Berson D, Yonehara K, Awatramani GB (2021). Rapid multi-directed cholinergic transmission in the central nervous system. Nat Commun, 12(1), 1374.
- Richter K, Ogiemwonyi-Schaefer R, Wilker S, Chaveiro AI, Agn A, Hecker M, Reichert M, Amati AL, Schlter KD, Manzini I, Schmalzing G, McIntosh JM, Padberg W, Grau V, Hecker A (2020). Amyloid Beta Peptide (Aβ1-42) Reverses the Cholinergic Control of Monocytic IL-1β Release. J Clin Med, 9(9).
- Zheng N, Christensen SB, Blakely A, Dowell C, Purushottam L, McIntosh JM, Chou DH (2020). Development of Conformationally Constrained α-RgIA Analogues as Stable Peptide Antagonists of Human α9α10 Nicotinic Acetylcholine Receptors. J Med Chem, 63(15), 8380-8387.
- Yu Z, McIntosh JM, Sadeghi SG, Glowatzki E (2020). Efferent synaptic transmission at the vestibular type II hair cell synapse. J Neurophysiol, 124(2), 360-374.
- Bjrn-Yoshimoto WE, Ramiro IBL, Yandell M, McIntosh JM, Olivera BM, Ellgaard L, Safavi-Hemami H (2020). Curses or Cures: A Review of the Numerous Benefits Versus the Biosecurity Concerns of Conotoxin Research. Biomedicines, 8(8).
- Hone AJ, Rueda-Ruzafa L, Gordon TJ, Gajewiak J, Christensen S, Dyhring T, Albillos A, McIntosh JM (2020). Expression of α3β2β4 nicotinic acetylcholine receptors by rat adrenal chromaffin cells determined using novel conopeptide antagonists. J Neurochem, 154(2), 158-176.
- Rybin MJ, OBrien H, Ramiro IBL, Azam L, McIntosh JM, Olivera BM, Safavi-Hemami H, Yoshikami D (2020). αM-Conotoxin MIIIJ Blocks Nicotinic Acetylcholine Receptors at Neuromuscular Junctions of Frog and Fish. Toxins (Basel), 12(3).
- Donvito G, Muldoon PP, Jackson KJ, Ahmad U, Zaveri NT, McIntosh JM, Chen X, Lichtman AH, Damaj MI (2018). Neuronal nicotinic acetylcholine receptors mediate ∆9 -THC dependence: Mouse and human studies. Addict Biol, 25(1), e12691.
- Toma W, Ulker E, Alqasem M, AlSharari SD, McIntosh JM, Damaj MI (2020). Behavioral and Molecular Basis of Cholinergic Modulation of Pain: Focus on Nicotinic Acetylcholine Receptors. Curr Top Behav Neurosci, 45, 153-166.
- Huynh PN, Giuvelis D, Christensen S, Tucker KL, McIntosh JM (2019). RgIA4 Accelerates Recovery from Paclitaxel-Induced Neuropathic Pain in Rats. Mar Drugs, 18(1).
- van Hout M, Valdes A, Christensen SB, Tran PT, Watkins M, Gajewiak J, Jensen AA, Olivera BM, McIntosh JM (2019). α-Conotoxin VnIB from Conus ventricosus is a potent and selective antagonist of α6β4* nicotinic acetylcholine receptors. Neuropharmacology, 157, 107691.
- Peng C, Yan Y, Kim VJ, Engle SE, Berry JN, McIntosh JM, Neve RL, Drenan RM (2018). Gene editing vectors for studying nicotinic acetylcholine receptors in cholinergic transmission. Eur J Neurosci, 50(3), 2224-2238.
- Hone AJ, Fisher F, Christensen S, Gajewiak J, Larkin D, Whiteaker P, McIntosh JM (2019). PeIA-5466: A Novel Peptide Antagonist Containing Non-natural Amino Acids That Selectively Targets α3β2 Nicotinic Acetylcholine Receptors. J Med Chem, 62(13), 6262-6275.
- Zakrzewicz A, Richter K, Zakrzewicz D, Siebers K, Damm J, Agn A, Hecker A, McIntosh JM, Chamulitrat W, Krasteva-Christ G, Manzini I, Tikkanen R, Padberg W, Janciauskiene S, Grau V (2019). SLPI Inhibits ATP-Mediated Maturation of IL-1β in Human Monocytic Leukocytes: A Novel Function of an Old Player. Front Immunol, 10, 664.
- Grau V, Richter K, Hone AJ, McIntosh JM (2019). Conopeptides [V11L;V16D]ArIB and RgIA4: Powerful Tools for the Identification of Novel Nicotinic Acetylcholine Receptors in Monocytes. Front Pharmacol, 9, 1499.
- Arribas-Blzquez M, Olivos-Or LA, Barahona MV, Snchez de la Muela M, Solar V, Jimnez E, Gualix J, McIntosh JM, Ferrer-Montiel A, Miras-Portugal MT, Artalejo AR (2019). Overexpression of P2X3 and P2X7 Receptors and TRPV1 Channels in Adrenomedullary Chromaffin Cells in a Rat Model of Neuropathic Pain. Int J Mol Sci, 20(1).
- Bavo F, Pucci S, Fasoli F, Lammi C, Moretti M, Mucchietto V, Lattuada D, Viani P, De Palma C, Budriesi R, Corradini I, Dowell C, McIntosh JM, Clementi F, Bolchi C, Gotti C, Pallavicini M (2018). Potent Antiglioblastoma Agents by Hybridizing the Onium-Alkyloxy-Stilbene Based Structures of an α7-nAChR, α9-nAChR Antagonist and of a Pro-Oxidant Mitocan. J Med Chem, 61(23), 10531-10544.
- Hone AJ, Talley TT, Bobango J, Huidobro Melo C, Hararah F, Gajewiak J, Christensen S, Harvey PJ, Craik DJ, McIntosh JM (2018). Molecular determinants of α-conotoxin potency for inhibition of human and rat α6β4 nicotinic acetylcholine receptors. J Biol Chem, 293(46), 17838-17852.
- Chen DJ, Gao FF, Ma XK, Shi GG, Huang YB, Su QX, Sudweeks S, Gao M, Dharshaun T, Eaton JB, Chang YC, Mcintosh JM, Lukas RJ, Whiteaker P, Steffensen SC, Wu J (2018). Pharmacological and functional comparisons of α6/α3β2β3-nAChRs and α4β2-nAChRs heterologously expressed in the human epithelial SH-EP1 cell line. Acta Pharmacol Sin, 39(10), 1571-1581.
- Richter K, Koch C, Perniss A, Wolf PM, Schweda EKH, Wichmann S, Wilker S, Magel I, Sander M, McIntosh JM, Padberg W, Grau V (2018). Phosphocholine-Modified Lipooligosaccharides of Haemophilus influenzae Inhibit ATP-Induced IL-1β Release by Pulmonary Epithelial Cells. Molecules, 23(8).
- Richter K, Sagawe S, Hecker A, Kllmar M, Askevold I, Damm J, Heldmann S, Phlmann M, Ruhrmann S, Sander M, Schlter KD, Wilker S, Knig IR, Kummer W, Padberg W, Hone AJ, McIntosh JM, Zakrzewicz AT, Koch C, Grau V (2018). C-Reactive Protein Stimulates Nicotinic Acetylcholine Receptors to Control ATP-Mediated Monocytic Inflammasome Activation. Front Immunol, 9, 1604.
- Yan Y, Peng C, Arvin MC, Jin XT, Kim VJ, Ramsey MD, Wang Y, Banala S, Wokosin DL, McIntosh JM, Lavis LD, Drenan RM (2017). Nicotinic Cholinergic Receptors in VTA Glutamate Neurons Modulate Excitatory Transmission. Cell Rep, 23(8), 2236-2244.
- Siebers K, Fink B, Zakrzewicz A, Agn A, Richter K, Konzok S, Hecker A, Zukunft S, Kllmar M, Klein J, McIntosh JM, Timm T, Sewald K, Padberg W, Aggarwal N, Chamulitrat W, Santoso S, Xia W, Janciauskiene S, Grau V (2018). Alpha-1 Antitrypsin Inhibits ATP-Mediated Release of Interleukin-1β via CD36 and Nicotinic Acetylcholine Receptors. Front Immunol, 9, 877.
- Romero HK, Christensen SB, Di Cesare Mannelli L, Gajewiak J, Ramachandra R, Elmslie KS, Vetter DE, Ghelardini C, Iadonato SP, Mercado JL, Olivera BM, McIntosh JM (2017). Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain. Proc Natl Acad Sci U S A, 114(10), E1825-E1832.
- Pang X, Liu L, Ngolab J, Zhao-Shea R, McIntosh JM, Gardner PD, Tapper AR (2016). Habenula cholinergic neurons regulate anxiety during nicotine withdrawal via nicotinic acetylcholine receptors. Neuropharmacology, 107, 294-304.
- Baladi MG, Nielsen SM, McIntosh JM, Hanson GR, Fleckenstein AE (2016). Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors. Behav Pharmacol, 27(5), 422-30.
- Zhang D, McGregor M, Bordia T, Perez XA, McIntosh JM, Decker MW, Quik M (2015). α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Mov Disord, 30(14), 1901-1911.
- Grady SR, Meinerz NM, Cao J, Reynolds AM, Picciotto MR, Changeux JP, McIntosh JM, Marks MJ, Collins AC (2001). Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum. J Neurochem, 76(1), 258-68.
Other
- Jimnez-Pompa A, Sanz-Lzaro S, Omodolor RE, Medina-Polo J, Gonzlez-Enguita C, Blzquez J, McIntosh JM, Albillos A (2021). Cross Talk between α7 and α3β4 Nicotinic Receptors Prevents Their Desensitization in Human Chromaffin Cells. J Neurosci (42(7), pp. 1173-1183). United States.
- Sethuramanujam S, Matsumoto A, deRosenroll G, Murphy-Baum B, Grosman C, McIntosh JM, Jing M, Li Y, Berson D, Yonehara K, Awatramani GB (2021). Author Correction: Rapid multi-directed cholinergic transmission in the central nervous system. Nat Commun (12(1), p. 2441). England.
Patent
- Maren Watkins, Baldomero M. Olivera, David R. Hillyard, J. Michael McIntosh, Robert M. Jones (2013). Alpha-conotoxin Peptides. U.S. Patent No. 8487075. Washington, D.C.:U.S. Patent and Trademark Office.
- J. Michael MCINTOSH, Baldomero M. OLIVERA, Michael ELLISON, Michelle A. VINCLER (2012). CONOTOXIN PEPTIDES. U.S. Patent No. 20120220539. Washington, D.C.:U.S. Patent and Trademark Office.
- J. Michael McIntosh (2012). ALPHA-CONOTOXIN MII ANALOGS. U.S. Patent No. 20120122803. Washington, D.C.:U.S. Patent and Trademark Office.
- McIntosh JM (2012). Alpha-conotoxin Peptides. U.S. Patent No. US 8110549 B2. Washington, D.C.:U.S. Patent and Trademark Office.
- McIntosh, JM (2012). Alpha-conotoxin Analogs. U.S. Patent No. US 8101,573 B2. Washington, D.C.:U.S. Patent and Trademark Office.
- McIntosh, JM (2011). Alpha-conotoxin Peptides. U.S. Patent No. US 7902153 B. Washington, D.C.:U.S. Patent and Trademark Office.
- McIntosh JM (2008). ¿-Conotoxin MII analogues. U.S. Patent No. U.S. Patent 7,387,997. Washington, D.C.:U.S. Patent and Trademark Office.
- McIntosh JM (2008). Conotoxin peptides. U.S. Patent No. U.S. Patent 7,368,432. Washington, D.C.:U.S. Patent and Trademark Office.
- Watkins M, Olivera BM, Hillyard DR, McIntosh JM, Jones RM (2007). Alpha-conotoxin peptides. U.S. Patent No. United States Patent 7279549. Washington, D.C.:U.S. Patent and Trademark Office.
- Olivera BM, McIntosh JM, Yoshikami D, Cartier GE, Luo S (2005). Uses of .alpha.-conotoxin peptide. U.S. Patent No. 6,958,323. Washington, D.C.:U.S. Patent and Trademark Office.
- Olivera BM, Layer RT, McIntosh JM, Nielsen JS, Jones RM (2005). .alpha.-conotoxin peptides. U.S. Patent No. 6,855,805. Washington, D.C.:U.S. Patent and Trademark Office.
- Watkins M, Olivera BM, Hillyard DR, McIntosh JM, Jones RM (2004). .alpha.-conotoxin peptides. U.S. Patent No. 6,797,808. Washington, D.C.:U.S. Patent and Trademark Office.
- Walker CS, Shetty R, Jimenez EC, McIntosh JM, Olivera BM, Watkins M, Jones RM, Shen GS (2004). I-superfamily conotoxins. U.S. Patent No. 6,767,895. Washington, D.C.:U.S. Patent and Trademark Office.
- McIntosh JM, Olivera BM, Cruz LJ, Corpuz GP, Jones RM, Garrett JE (2004). Conotoxin peptides. U.S. Patent No. 6,767,896. Washington, D.C.:U.S. Patent and Trademark Office.
- McIntosh JM, et al (2004). Alpha-Conotoxin Peptides (Australia). U.S. Patent No. 770,076. Washington, D.C.:U.S. Patent and Trademark Office.
- Olivera BM, McIntosh JM, Garrett JE, Cruz LJ, Jones RM, Cartier GE, Wagstaff JD (2004). Mu-conopeptides. U.S. Patent No. 6,727,226. Washington, D.C.:U.S. Patent and Trademark Office.
- Olivera BM, Cartier GE, Watkins M, Hillyard DR, McIntosh JM, Layer RT, Jones RM (2004). O-superfamily conotoxin peptides. U.S. Patent No. 6,762,165. Washington, D.C.:U.S. Patent and Trademark Office.
- McIntosh JM (2004). O-superfamily conotoxin peptides. U.S. Patent No. U.S. Patent 6,762,165. Washington, D.C.:U.S. Patent and Trademark Office.
- McCabe RT, Zhou L-M, Layer RT, Olivera BM, McIntosh JM (2002). Use of conantokins. U.S. Patent No. 6,399,574. Washington, D.C.:U.S. Patent and Trademark Office.
- Olivera BM, McIntosh JM, McCabe RT, Layer RT, Zhou L-M (2001). Use of conantokins for treating pain. U.S. Patent No. 6,277,825. Washington, D.C.:U.S. Patent and Trademark Office.
- Olivera BM, Layer RT, Watkins M, Hillyard DR, McIntosh JM, Schoenfeld R, Jones RM (2001). .alpha.-conotoxin peptides. U.S. Patent No. 6,268,473. Washington, D.C.:U.S. Patent and Trademark Office.
- Olivera BM, McIntosh JM, Yoshikami D, Cartier GE, Luo S (2001). Uses of .alpha.-conotoxin peptides. U.S. Patent No. 6,265,541. Washington, D.C.:U.S. Patent and Trademark Office.
- McCabe RT, Zhou L-M, Layer RT, Olivera BM, McIntosh JM (2001). Use of conantokins. U.S. Patent No. 6,172,041. Washington, D.C.:U.S. Patent and Trademark Office.
- Shon K-J, Olivera BM, McIntosh JM (1999). Conotoxin peptides. U.S. Patent No. 5,990,295. Washington, D.C.:U.S. Patent and Trademark Office.
- McIntosh JM, Kulak JM, Yoshikami D, Olivera BM (1999). Use of .alpha.-conotoxin MII to treat disorders resulting from nicotine-stimulated dopamine release. U.S. Patent No. 5,929,034. Washington, D.C.:U.S. Patent and Trademark Office.
- McIntosh JM, Kulak JM, Yoshikami D, Olivera BM (1999). Use of .alpha.-conotoxin MII to treat disorders resulting from nicotine-stimulated dopamine release. U.S. Patent No. 5,922,679. Washington, D.C.:U.S. Patent and Trademark Office.
- Cruz LJ, Olivera BM, McIntosh JM, Jimenez E, Craig AG, Rivier JA, Julius D, England L (1999). Bromo-tryptophan conopeptides. U.S. Patent No. 5,889,147. Washington, D.C.:U.S. Patent and Trademark Office.
- McIntosh JM, Cartier GE, Yoshikami D, Luo S, Olivera BM (1999). Conopeptides AuIA, AuIB and AuIC. U.S. Patent No. 5,866,682. Washington, D.C.:U.S. Patent and Trademark Office.
- McIntosh JM, Kulak JM, Yoshikami D, Olivera BM (1998). Use of .alpha.-conotoxin MII to treat disorders resulting from nicotine stimulated dopamine release. U.S. Patent No. 5,780,433. Washington, D.C.:U.S. Patent and Trademark Office.
- Shon K-J, Olivera BM, McIntosh JM, Hasson A, Spira ME (1998). Conotoxin peptides. U.S. Patent No. 5,719,264. Washington, D.C.:U.S. Patent and Trademark Office.
- Olivera BM, Cruz LJ, Hillyard DR, McIntosh JM, Santos AO (1997). Conotoxin peptides. U.S. Patent No. 5,633,347. Washington, D.C.:U.S. Patent and Trademark Office.
- Olivera BM, Cruz LJ, Hillyard DR, McIntosh JM, Santos AD (1997). Conotoxin peptides. U.S. Patent No. 5,595,972. Washington, D.C.:U.S. Patent and Trademark Office.
- Olivera BM, Cruz LJ, Hillyard DR, McIntosh JM, Santos AD (1996). Process and primers for identifying nucleic acids encoding A-lineage conotoxin peptides. U.S. Patent No. 5,589,340. Washington, D.C.:U.S. Patent and Trademark Office.
- Olivera BM, Cruz LJ, Hillyard DR, McIntosh JM, Santos AD (1996). Conotoxin Peptides. U.S. Patent No. 5,514,774. Washington, D.C.:U.S. Patent and Trademark Office.